Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.

Abstract excerpt

Mutations in FMS-related receptor tyrosine kinase 3 (FLT3) are among the most common alterations in acute myeloid leukemia (AML), present in ≈30% of newly diagnosed AML cases. Internal tandem duplications (ITD) in FLT3 (FLT3-ITD) occur in ≈25% of newly diagnosed AML cases and are associated with unfavorable outcomes. Quizartinib (formerly AC220) is a novel, second-generation, highly potent, and selective type II...

Topics

• Animals
• Humans
• Antineoplastic Agents
• Benzothiazoles
• fms-Like Tyrosine Kinase 3
• Leukemia, Myeloid, Acute
• Mutation
• Phenylurea Compounds
• Tyrosine Kinase Inhibitors